Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

13. november 2026 opdateret af: Finzelberg GmbH & Co. KG

The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.

Studieoversigt

Detaljeret beskrivelse

This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.

Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.

Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.

Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

78

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Cork, Irland
        • Atlantia Clinical Trials
        • Kontakt:
    • RLP
      • Andernach, RLP, Tyskland, 56626
        • Finzelberg

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Be able to give written informed consent.
  2. Be between 18-70 years of age.
  3. BMI between 18.5 and 30.0 kg/m2
  4. Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
  5. Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.

Exclusion Criteria:

  1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.

  2. Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.

  3. Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)

  4. Participants that are habitual smokers or vapers

  5. High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day

  6. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  7. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:

    1. Uncontrolled hypertension
    2. Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
    3. Diagnosed cognitive impairment
    4. Type I or II diabetes
    5. Clinically significant cardiovascular, liver and renal disease
    6. Diagnosed gastrointestinal conditions (IBD, coeliac disease)
  8. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:

    a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)

  9. Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:

    1. Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
    2. Products containing Sideritis, Sage, Thymus and Oregano
  10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

  11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Placebo supplement containing carrier material only

Placebo supplement containing carrier material only

Eksperimentel: Siderits

Sideritis supplement administered at an estimated daily dose

Sideritis scardica preparation (Greek Mountain Tea)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
Tidsramme: Baseline, day 1, day 7

Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)

Baseline, day 1, day 7

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cognitive performance during the test called Choice Reaction Time (CRT)
Tidsramme: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%)

Baseline, day 1, day 7
Cognitive Performance: Rapid Visual Information Processing (RVIP)
Tidsramme: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits)

Baseline, day 1, day 7
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenation
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. marts 2027

Studieafslutning (Anslået)

1. maj 2027

Datoer for studieregistrering

Først indsendt

30. oktober 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • FB_AF216

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.

IPD-delingstidsramme

Start date: Following completion of the study and publication of the primary study results.

End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.

IPD-delingsadgangskriterier

Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner